Navigation Links
Roche's Investigational Polymerase Inhibitor, Combined with PEGASYS(R) and COPEGUS(TM), Shows Potent Antiviral Activity in Treatment of Chronic Hepatitis C at Four Weeks
Date:11/2/2007

- Roche progresses R1626 into phase IIb study, called POLI 1 -

BOSTON, Nov. 2 /PRNewswire/ -- R1626, one of Roche's new investigational drugs for chronic hepatitis C virus (HCV) infection, has shown promising antiviral activity when given in combination with PEGASYS(R) (peginterferon alfa-2a) and COPEGUS(TM) (ribavirin), according to results being presented at the American Association for the Study of the Liver Disease (AASLD) meeting, being held in Boston, Nov. 2-6. After four weeks of treatment with this triple combination, the virus could no longer be detected in up to 81 percent of patients, with a mean decrease in viral load of 5.2 log10 from baseline. This is indicative of a robust virological response, and R1626 is being progressed into Phase IIb study as a result of these findings.

R1626 belongs to a class of antivirals called polymerase inhibitors, which are being investigated in combination with the current standard of care, pegylated interferon and ribavirin. The hope is that this combination will increase the number of patients who are able to be successfully treated for hepatitis C.

"The results from this Phase IIa study show that R1626 has a profound antiviral effect when used in combination with PEGASYS plus COPEGUS," said Dr. Paul Pockros, Scripps Clinic, San Diego, California, the lead investigator of the study. "This effect of R1626 in combination therapy, along with the lack of resistance observed to date, means that R1626 could be an exciting drug for patients with hepatitis C, if a safe and acceptable dosing regimen can be determined in future studies."

Antiviral Activity and Safety Results Being Presented at AASLD

The multicenter Phase IIa study enrolled patients with genotype 1 chronic HCV who have not previously received treatment. The objectives were to evaluate the four-week activity and safety of combining R1626 with PEGASYS alone or R1626 with PEGASYS plus COPEGUS in comparison to PEGASYS/COPEGUS,
'/>"/>

SOURCE Roche
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
2. An Investigational Study Released at ADA Showed that Initial Combination Therapy with Januvia (sitagliptin) and Metformin Led to Improvement in Markers of Beta Cell Function in Patients with Type 2 Diabetes
3. Late Breaking Data Released at ADA Showed that the Investigational Use of Januvia and Metformin as Initial Combination Therapy Provided Significant Glucose Lowering Efficacy over 54 Weeks in Patients with Type 2 Diabetes
4. Investigational Study Demonstrated a Re-Establishment of Clinical Improvement with Orencia (Abatacept) in Children with Juvenile Idiopathic Arthritis upon Re-Introduction of Therapy
5. Mercks Investigational Migraine Treatment MK-0974 Significantly Improved Migraine Pain on Several Efficacy Measures in a Phase II Study
6. Data Demonstrated Metastatic Melanoma Response to Investigational Immunotherapy Ipilimumab
7. Investigational Drug Cediranib (AZD2171) Shows Promise in Patients With Recurrent Glioblastoma (GBM)
8. Additional New Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at ASCO Annual Meeting
9. Additional New Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at ASCO Annual Meeting
10. Investigational Cancer Drug Pertuzumab Shows Promising Results in Advanced Breast Cancer When Combined with Herceptin
11. Shire Announces Positive Results of Studies With Guanfacine Extended Release, An Investigational Nonstimulant Medication Filed for the Treatment of ADHD in Children and Adolescents
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... UPI ), a medical device company that develops, ... dysfunctions, today reported financial results for the fiscal 2015 ... for the Company,s Urgent ®  PC Neuromodulation System grew ... as compared to $3.9 million in the third quarter ...
(Date:1/22/2015)... , Jan. 22, 2015  Amgen (NASDAQ: AMGN ) ... year 2014 financial results on Tuesday, Jan. 27, 2015, after the ... by a conference call with the investment community at 2 p.m. ... A. Bradway , chairman and chief executive officer, and other members ...
(Date:1/22/2015)... 2015 Increasing sophistication among enterprise buyers of language ... in 2015, says Moravia CMO, Renato ... by market research firm Common Sense Advisory, 15 percent ... translation and localization needs. "From a language industry perspective, ...
Breaking Medicine Technology:Uroplasty Reports Record Revenue in Fiscal Third Quarter 2Uroplasty Reports Record Revenue in Fiscal Third Quarter 3Uroplasty Reports Record Revenue in Fiscal Third Quarter 4Uroplasty Reports Record Revenue in Fiscal Third Quarter 5Uroplasty Reports Record Revenue in Fiscal Third Quarter 6Uroplasty Reports Record Revenue in Fiscal Third Quarter 7Uroplasty Reports Record Revenue in Fiscal Third Quarter 8Uroplasty Reports Record Revenue in Fiscal Third Quarter 9Uroplasty Reports Record Revenue in Fiscal Third Quarter 10Uroplasty Reports Record Revenue in Fiscal Third Quarter 11Uroplasty Reports Record Revenue in Fiscal Third Quarter 12Uroplasty Reports Record Revenue in Fiscal Third Quarter 13Uroplasty Reports Record Revenue in Fiscal Third Quarter 14Uroplasty Reports Record Revenue in Fiscal Third Quarter 15Uroplasty Reports Record Revenue in Fiscal Third Quarter 16Uroplasty Reports Record Revenue in Fiscal Third Quarter 17Uroplasty Reports Record Revenue in Fiscal Third Quarter 18Amgen Announces Webcast of 2014 Fourth Quarter and Full Year Financial Results 2Moravia Sees Single-Sourcing as Key Localization Trend in 2015 2
... Business Unit Realignment, Completed; Clinical Update Provided for NicVAX Phase 2b ... ... BOCA RATON, Fla., Aug. 1 Nabi,Biopharmaceuticals (Nasdaq: NABI ) ... from continuing,operations of $5.3 million, or $0.09 per share, for the quarter ...
... to Help People Kick the Habit, HOUSTON, ... it,is offering an affordable new program to help ... plan, available at RediClinics,nationwide, includes, when appropriate, a ... chance of successfully quitting. According to the ...
Cached Medicine Technology:Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results 2Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results 3Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results 4Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results 5Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results 6Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results 7Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results 8Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results 9Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results 10Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results 11Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results 12Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results 13RediClinic Offers Affordable New Plan Clinically Shown to Double a Person's Chance to Stop Smoking 2RediClinic Offers Affordable New Plan Clinically Shown to Double a Person's Chance to Stop Smoking 3
(Date:1/22/2015)... 2015 As interest in the value of ... momentum worldwide, Rev. Eric J. Hall , president and ... (HCCN), will be the keynote speaker on January 27 at ... health system. , The conference, “Hope and Resilience: Innovative and ...
(Date:1/22/2015)... has released a new blog post presenting a list of vehicles ... , Some types of vehicles cannot be covered under an ... post to see if their vehicle qualifies for auto insurance coverage. ... the cars that cannot be covered by a plan. Clients have ...
(Date:1/22/2015)... 2015 Step into a macabre world ... Museum of Virginia. Wicked Plants, the Museum’s latest featured ... 75 poisonous, carnivorous and diabolical plants inside of a ... uncover the biochemical, physical and neurological processes between botanicals ...
(Date:12/26/2014)... December 26, 2014 The US represents the ... report. In 2013, GlobalData’s forecast estimates that sales of branded ... market due to the high incidence of the disease, high ... 5EU, Japan, and China. Increased sales of CRC therapies over ...
(Date:12/26/2014)... 2014 Cooking and warming equipment ... This score reflects slightly positive negotiation conditions for buyers, stemming ... and a low level of price volatility. “However, buyer power ... and warming equipment and high volatility in the world price ...
Breaking Medicine News(10 mins):Health News:HealthCare Chaplaincy CEO to Keynote Spiritual Care Summit in Israel 2Health News:HealthCare Chaplaincy CEO to Keynote Spiritual Care Summit in Israel 3Health News:Some Vehicles Cannot Be Covered By An Auto Insurance Policy! 2Health News:Wicked Plants are taking over the Science Museum of Virginia 2Health News:US Colorectal Cancer Drug Market Analysis and Forecast to 2023 Report Available at ReportsnReports.com 2Health News:US Colorectal Cancer Drug Market Analysis and Forecast to 2023 Report Available at ReportsnReports.com 3Health News:US Colorectal Cancer Drug Market Analysis and Forecast to 2023 Report Available at ReportsnReports.com 4Health News:Cooking & Warming Equipment Procurement Category Market Research Report from IBISWorld has Been Updated 2Health News:Cooking & Warming Equipment Procurement Category Market Research Report from IBISWorld has Been Updated 3
... , ... A. Abelson says proposed curbs address an illusion instead of the real problem — ... ... personal injury lawyer in Maryland and Washington, DC, says proposed limits on damage awards ...
... benefit actually stems from overall healthier lifestyle remains unclear, , ... for infants are numerous and well-known, but researchers are finding ... mom,s health as well. , In fact, the latest study ... amounts of abdominal fat, even decades later. , The study, ...
... ... ... , ... DAYTON, N.J. , March 5 Mincing Overseas Spice Company of ...
... ... Link is Citizen Preparedness , ... Sacramento, CA (PRWEB) March 5, 2010 -- A majority of Californians have ... not done enough to make their homes safer and guard their personal finances in ...
... ... ... ... ...
... stem from the devices or patient error, FDA panel says ... insulin pumps used to treat diabetes should try to supply ... problems with the devices, an advisory panel to the U.S. ... devices are required to report when a device malfunctions or ...
Cached Medicine News:Health News:Congressional Concession On Medical Malpractice Awards Will Not Lower Health Care Costs And Will Hurt Patients' Rights, Washington, DC Attorney Says 2Health News:Congressional Concession On Medical Malpractice Awards Will Not Lower Health Care Costs And Will Hurt Patients' Rights, Washington, DC Attorney Says 3Health News:Breast-Feeding Helps Mom Stay Slimmer Later in Life 2Health News:Breast-Feeding Helps Mom Stay Slimmer Later in Life 3Health News:Mincing Overseas Spice Company Voluntarily Recalls Two Lots of Black Pepper 2Health News:Study Reveals Californians Must Increase Earthquake Preparedness; Less Than 20 Percent Have Prepared Their Homes; Only 40 Percent Have Sufficient Water 2Health News:Study Reveals Californians Must Increase Earthquake Preparedness; Less Than 20 Percent Have Prepared Their Homes; Only 40 Percent Have Sufficient Water 3Health News:Study Reveals Californians Must Increase Earthquake Preparedness; Less Than 20 Percent Have Prepared Their Homes; Only 40 Percent Have Sufficient Water 4Health News:Study Reveals Californians Must Increase Earthquake Preparedness; Less Than 20 Percent Have Prepared Their Homes; Only 40 Percent Have Sufficient Water 5Health News:Endo to Present at Cowen and Company 30th Annual Health Care Conference 2Health News:Endo to Present at Cowen and Company 30th Annual Health Care Conference 3Health News:More Info Needed on Problems With Insulin Pumps 2Health News:More Info Needed on Problems With Insulin Pumps 3
Asymmetrical concave inner surface to conform to globe. Used in conjunction with the E5381 700 Circling Band (240 style). Indications: Wide scleral bed. Outside diameter 31.7 mm....
Used in conjunction with the E5381 700 Circling Band (240 style). Indications: Narrow scleral bed. Overall length: 100 mm, 3.9 inches....
Used in conjunction with the E5381 600 Circling Band (40 style). Indications: When high buckle is required. Overall length: 14.0 mm....
Used in conjunction with the E5381 600 Circling Band (40 style). Indications: Massive retinal breaks. Inner diameter: 26 mm....
Medicine Products: